Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
REGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$476.49 - $1,211.20
Previous CloseN/A
Volume208.99K
Average Volume (3M)1.40M
Market Cap
$56.17B
Enterprise Value$53.72B
Total Cash (Recent Filing)$8.35B
Total Debt (Recent Filing)$2.70B
Price to Earnings (P/E)13.3
Beta0.66
Next Earnings
Aug 01, 2025EPS Estimate
8.57Last Dividend Ex-Date
May 20, 2025Dividend Yield0.67%
Share Statistics
EPS (TTM)8.22
Shares Outstanding106,148,350
10 Day Avg. Volume1,132,689
30 Day Avg. Volume1,398,169
Financial Highlights & Ratios
PEG Ratio5.62
Price to Book (P/B)1.85
Price to Sales (P/S)0.00
P/FCF Ratio17.92
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit4.49
Enterprise Value/Ebitda2.81
Forecast
1Y Price Target
$732.10Price Target Upside40.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
Regeneron News
Bulls Say, Bears Say
Bulls Say
Investment PotentialDupixent, Eylea and cash on hand alone support valuation well above current levels even if zero pipeline contribution from the rest of the portfolio is assumed.
Product DevelopmentREGN reported highly encouraging initial Ph2 results for both of its Factor XI antibody candidates, indicating strong progress in their development pipeline.
Tax And Financial StrategyREGN's non-GAAP tax rate is lower than expected due to high employee stock compensation and significant R&D tax credits.
Bears Say
Competitive ChallengesThere is a 2-3 year delay expected for itepekimab due to a setback, with a slower ramp and lower peak sales anticipated given increased competition.
Market DynamicsInvestor concerns remain due to the lack of a randomized controlled trial for the monthly dosing of Eylea HD.
Regulatory RisksREGN and its partner face potential U.S. tariff exposure on Dupixent supply in 2026 if pharmaceutical tariffs are imposed.
Ownership Overview
0.28% Insiders
29.70% Mutual Funds
19.26% Other Institutional Investors
24.32% Public Companies and Individual Investors
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $476.49 and its highest was $1211.20 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $56.17B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Aug 01, 2025 which is in 35 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Apr 29, 2025. The company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.622 by -$0.402.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron pays a Quarterly dividend of $0.88 which represents an annual dividend yield of 0.67%. See more information on Regeneron dividends here
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 8.57.
How many shares outstanding does Regeneron have?
Regeneron has 106,148,350 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $8.22 in its last earnings report, missing expectations of $8.622. Following the earnings report the stock price went down -6.868%.
Which hedge fund is a major shareholder of Regeneron?
Currently, no hedge funds are holding shares in REGN
Regeneron Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$732.10 (40.71% Upside)
$732.10 (40.71% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 233.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.29%
12-Months-Change
Fundamentals
Return on Equity
15.96%
Trailing 12-Months
Asset Growth
9.24%
Trailing 12-Months
Company Description
Regeneron
Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company that specializes in discovering, developing, and delivering innovative medicines for serious medical conditions. Founded in 1988 and headquartered in Tarrytown, New York, Regeneron operates primarily in the pharmaceutical and biotechnology sectors. The company's core products include treatments for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular ailments, and infectious diseases. Regeneron's flagship products include EYLEA for retinal diseases, Dupixent for various allergic and inflammatory conditions, and Libtayo for certain types of cancer.
REGN Company Deck
REGN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong growth in key products like Dupixent and promising pipeline advancements. However, significant challenges were highlighted, including a decline in EYLEA sales, regulatory delays for EYLEA HD, and issues with patient assistance funding. Financial stability remains strong, but the balance of highlights and lowlights points to ongoing challenges that need to be addressed.Read More>REGN Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
REGN Stock 12 Month Forecast
Average Price Target
$732.10
▲(40.71%Upside)